Several large meta-analyses examining heterogenous treatment effects in placebo-controlled CVOTs have been conducted for GLP1-RA73,80,81,87–94, with the majority of studies focusing on whether prior established CVD modifies the relative effect of GLP1-RA on MACE and/or heart failure. The gene discussed is GLP1R; the disease is heart failure.